TCDpharma

Press Release

TCD Pharma Receives FDA IND Approval for New Cancer Drug

TCD-717, a Novel ChoKα Inhibitor, to Begin Phase I Study in Cancer Patients in the US

Madrid, Spain, September 28, 2010 – Traslational Cancer Drugs Pharma, S.L., ("TCD") has announced today that the FDA has approved its Investigational New Drug (IND) application to begin a Phase I clinical study with its Choline Kinase Alpha inhibitor, TCD-717, for the treatment of solid tumors.

The clinical development plan for TCD-717 is designed to expedite the drug candidate through the clinical development path. The Phase I trial will be conducted in two medical centers in the US and will assess the safety and pharmacokinetic profile of TCD-717 administered intravenously over four hours. In preclinical testing, TCD-717 has demonstrated marked anti-cancer activity in xenograft models of lung cancer, colon cancer, breast cancer and bladder cancer.

"TCD-717 shows tremendous potential for the treatment of a wide range of cancers," said Ran Vigdor, CEO of TCD, "The compound has also demonstrated promising synergistic effects with standard chemotherapy in different indications suggesting it could have significant benefit in combination with standard treatments. We believe TCD-717 is an exciting and worthy first candidate generated by the Company".

TCD-717 is a novel, first-in-class, precisely-targeted small-molecule inhibitor of Choline Kinase Alpha (ChoKα). ChoKα is an enzyme centrally involved in regulating the production of phosphatidylcholine (a key building block in the formation of the cell's membrane). TCD has demonstrated that ChoKα is crucial to a number of processes involved in cancer including independent cell proliferation, evasion of apoptosis, increased cell motility and metastasis. Moreover, the Company has shown that inhibition of ChoKα while merely temporarily arresting the cell cycle in normal cells, results in a toxic effect leading to cell death in cancer cells.

With ChoKα and TCD-717, TCD is employing a personalized and targeted treatment strategy – the patient's eligibility for the treatment is determined by qRT-PCR analysis of tumor samples for ChoKα overexpression. Once eligibility is established, TCD-717 would then be administered resulting in the targeted destruction of tumor cells whilst leaving normal cells unharmed.

About TCD:
Traslational Cancer Drugs Pharma S.L ("TCD" or the "Company") is a biotechnology corporation focused on the discovery, development and commercialization of innovative therapies that address unmet medical needs in the field of Oncology.

TCD's strategy is to identify, evaluate and in-license breakthrough discoveries and to rapidly advance them through the completion of Phase II clinical trials of the Regulatory process. This is done by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, resulting in an efficient, flexible and effective process. Value to shareholders is generated by royalty-bearing licensing agreements.

TCD is currently positioning itself as a Spain's Partner of Choice for Oncology drug discovery and development opportunities. The aim of the Company is to build its pipeline through in-licensing of cutting edge technology, with clear commercial rationale after proof-of-concept has been reached.

This press release contains "forward-looking" statements, including statements with respect to the further development and potential safety and efficacy of TCD-717, in the treatment of cancer and TCD's development strategy. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of TCD to differ materially from those indicated by these forward-looking statements, including, among others, the risk that the U.S. Food and Drug Administration may require changes to the protocols and informed consents for clinical trials of TCD-717, which changes may have a material adverse effect on the timing of, and TCD's ability to conduct, those clinical trials, risks related to the clinical advancement of TCD-717, including, but not limited, to the risk that clinical trials for this product candidate may not demonstrate safety and efficacy sufficient to obtain the requisite regulatory approvals or to result in a marketable product and risks related to the potential for others to develop products containing or based on TCD-717. TCD does not undertake any obligation to update forward-looking statements.